|Assessment Status||Rapid Review Complete|
|Indication||Drospirenone/estetrol monohydrate is indicated for oral contraception.|
|Rapid review commissioned||07/12/2022|
|Rapid review completed||23/01/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that drospirenone/estetrol monohydrate not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement; June 2023